Fredag 1 Maj | 17:08:05 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-11 07:45 Bokslutskommuniké 2026
2026-10-22 07:45 Kvartalsrapport 2026-Q3
2026-07-17 07:45 Kvartalsrapport 2026-Q2
2026-04-30 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2026-04-29 - Årsstämma
2026-04-29 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-10-22 - Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-06-11 - Extra Bolagsstämma 2025
2025-04-30 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksam inom djurhälsa. Bolaget levererar, via sina dotterbolag, läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-04-29 07:45:00

Positive start to the year

  • Revenue increased by 8 per cent to EUR 116.0m (107.5) with organic growth of 9 per cent
  • Adjusted EBITA increased 3 per cent to EUR 29.2m (28.3) corresponding to a margin of 25.2 per cent (26.3)
  • Operating profit (EBIT) of EUR 21.2m (15.6)
  • Profit for the period of EUR 10.1m (4.7) and earnings per share before and after dilution EUR 0.02 (0.01)
  • Cash flow from operating activities of EUR 23.0m (17.1)

“Vimian is off to a good start to 2026 with positive momentum in our Group. We report 8 per cent total growth to EUR 116 million in revenues, with strong organic growth of 9 per cent. Three out of four segments deliver double-digit organic growth, ahead of the global animal health market, says Alireza Tajbakhsh, CEO Vimian Group, and continues:

“Adjusted EBITA grew 3 per cent to EUR 29.2 million at a margin of 25.2 per cent (26.3), impacted by our investments to drive growth in MedTech orthopedics and new market entries within Veterinary Services. We continued to deliver strong operational cash generation and completed two acquisitions in the quarter, adding in total EUR 10 million in annual revenues to the Group.”

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q1-report-2026/dial-in

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q1-report-2026

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.